Drug news
UCB files Cimzia for Psoriatic Arthritis at FDA and EMA
UCB announced two new regulatory filings with the FDA and with the European Medicines Agency to extend the marketing authorization for Cimzia (certolizumab pegol) for the treatment of adult patients with active Psoriatic Arthritis.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.